Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer
Clinical trial NCT04590781 · TERMINATED
Trial details
- NCT number
- NCT04590781
- Sponsor
- Xencor, Inc.
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-05-10
- Primary completion
- 2022-03-24
- Enrollment
- 4
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.